HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

Pharmaceuticals and medical devices manufacturer Johnson & Johnson (NYSE:JNJ) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 ...

Johnson & Johnson is a diversified healthcare ... alongside MedTech engaging in medical devices like cardiovascular solutions. Success stems from robust product portfolios, continuous innovation ...